Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | PepGen Inc. hält Jahreshauptversammlung, wählt Direktoren und bestätigt Wirtschaftsprüfer | - | Investing.com Deutsch | ||
Fr | PepGen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.05. | H.C. Wainwright cuts PepGen stock price target to $8, keeps Buy rating | 1 | Investing.com | ||
29.05. | PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate | 2 | Benzinga.com | ||
28.05. | PepGen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
20.05. | PepGen Appoints Kasra Kasraian As New Chief Technology Officer | 2 | RTTNews | ||
20.05. | PepGen appoints new CTO to advance therapies | 2 | Investing.com | ||
09.05. | PepGen stock price target cut to $14 from $16 by H.C. Wainwright | 2 | Investing.com | ||
PEPGEN Aktie jetzt für 0€ handeln | |||||
08.05. | PepGen GAAP EPS of -$0.92 misses by $0.20 | 1 | Seeking Alpha | ||
08.05. | PepGen Inc. Q1 Loss Increases, Misses Estimates | 1 | RTTNews | ||
08.05. | PepGen Inc. - 8-K, Current Report | - | SEC Filings | ||
08.05. | PepGen Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
04.03. | PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls | 3 | Benzinga.com | ||
04.03. | PepGen pauses UK arm of DMD trial that's already on hold in US | 1 | FierceBiotech | ||
04.03. | PepGen slides after pause on mid-stage Duchenne trial | 1 | Seeking Alpha | ||
04.03. | PepGen Inc. - 8-K, Current Report | - | SEC Filings | ||
24.02. | PepGen GAAP EPS of -$0.68 beats by $0.04 | 3 | Seeking Alpha | ||
24.02. | PepGen Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
24.02. | PepGen Drug Shows Signs of Topping Rivals in Rare Muscle Disease With No Approved Meds | 1 | MedCity News | ||
24.02. | PepGen stock price target cut to $14 by Stifel analysts | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 95,35 | +0,05 % | BioNTech: Milliardendeal mit Bristol Myers Squibb - Aktie schießt ins Plus | BioNTechs Aktien schießen in der US-Vorbörse am Montag regelrecht nach oben: Aktuell werden 106,10 Dollar notiert nach einem NASDAQ-Schlusskurs bei 95,81 Dollar vom Freitag. Der Grund für den Kursanstieg... ► Artikel lesen | |
CUREVAC | 3,830 | -0,83 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
AMGEN | 254,90 | +0,08 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
NOVAVAX | 6,520 | -0,20 % | Aktien New York: Rücksetzer nach US-Bonitätsabstufung verpufft | NEW YORK (dpa-AFX) - Die Abstufung der US-Kreditwürdigkeit durch Moody?s hat die Anleger in New York am Montag nicht lange beeindruckt. Benoit Anne, Anleiheexperte bei MFS Investment Management, verwies... ► Artikel lesen | |
BIOGEN | 116,70 | -0,09 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
VIVOSIM LABS | 1,600 | -100,00 % | VivoSim Labs, INC. - 10-K, Annual Report | ||
INOVIO PHARMACEUTICALS | 1,980 | -0,50 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
MAINZ BIOMED | 2,775 | -100,00 % | MAINZ BIOMED N.V. - 6-K, Report of foreign issuer | ||
VIKING THERAPEUTICS | 24,220 | -0,78 % | Viking Therapeutics auf Jefferies-Konferenz: Vielversprechendes Abnehm-Medikament | ||
INTELLIA THERAPEUTICS | 7,146 | +0,37 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 9,668 | -0,17 % | BioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland... ► Artikel lesen | |
TEMPUS AI | 54,74 | +0,51 % | Opening Bell: Constellation Energy, Vistra, Netflix, Applied Digital, Steel Dyn., Pony.ai, Tempus AI | Zum Wochenauftakt schwankten die US-Börsen zwischen neuen Zolldrohungen und der Hoffnung auf sinkende Zinsen. Zwar sorgte US-Präsident Trumps verschärfte Rhetorik im Handelsstreit mit China zunächst... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 38,180 | +1,17 % | FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector | WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT), Wednesday announced that the FDA has designated its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for limb-girdle... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 1,218 | -1,30 % | H.C. Wainwright initiates Cardiol Therapeutics stock with buy rating | ||
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,000 | +1,26 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 8-K, Current Report |